MBD-001

MBD-001 is an investigational gene therapy candidate being developed by Medera Biopharmaceutical for the treatment of pulmonary fibrosis. Currently in the preclinical stage, MBD-001 is designed as a disease-modifying therapy that utilizes an adeno-associated virus (AAV) vector to deliver a therapeutic transgene to lung tissue. The program aims to address the underlying biological drivers of fibrotic lung disease, potentially halting or reversing the progression of tissue scarring. Medera Biopharmaceutical, formed through the integration of Novoheart and Sardocor, leverages its expertise in genetic medicine and proprietary delivery technologies to develop this candidate. While the specific molecular target and transgene for MBD-001 have not been publicly disclosed, the therapy represents a novel approach to treating high-unmet-need respiratory conditions through genetic modulation.